Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9920 Pacific Heights Blvd, Suite 350, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - Apr 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.68 K % +170%
Debt-to-equity 4.06 % -66.2%
Return On Equity -18.4 % +62.1%
Return On Assets -17.7 % +59.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 110 M shares +10.7%
Common Stock, Shares, Outstanding 110 M shares +39%
Entity Public Float 93.7 M USD -52.2%
Common Stock, Value, Issued 1 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 103 M shares +32%
Weighted Average Number of Shares Outstanding, Diluted 103 M shares +32%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 76.9 M USD +46%
General and Administrative Expense 37.5 M USD +70.6%
Operating Income (Loss) -114 M USD -53.2%
Income Tax Expense (Benefit) 1 K USD 0%
Net Income (Loss) Attributable to Parent -93.7 M USD -29.6%
Earnings Per Share, Basic -0.92 USD/shares +2.13%
Earnings Per Share, Diluted -0.92 USD/shares +2.13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 196 M USD +965%
Assets, Current 966 M USD +547%
Operating Lease, Right-of-Use Asset 1.05 M USD -21.8%
Assets 968 M USD +541%
Accounts Payable, Current 5.23 M USD +37.5%
Liabilities, Current 32.8 M USD +109%
Operating Lease, Liability, Noncurrent 852 K USD -27.9%
Liabilities 33.6 M USD +99.8%
Retained Earnings (Accumulated Deficit) -405 M USD -30.1%
Stockholders' Equity Attributable to Parent 934 M USD +597%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 934 M USD +597%
Liabilities and Equity 968 M USD +541%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.13 M USD +75.1%
Net Cash Provided by (Used in) Financing Activities 606 M USD +14385%
Net Cash Provided by (Used in) Investing Activities -460 M USD -21019%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 110 M shares +39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3 M USD -31.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6 M USD +38.9%
Deferred Tax Assets, Valuation Allowance 119 M USD +32.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 119 M USD +32.1%
Operating Lease, Liability 1.18 M USD -20.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -94.7 M USD -32.4%
Operating Lease, Liability, Current 329 K USD +6.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.3 M USD +72%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) -22.3 M USD -38.7%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 1 K USD 0%
Current Federal Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Net of Valuation Allowance 315 K USD -20.7%
Deferred State and Local Income Tax Expense (Benefit) -6.79 M USD -12.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%